The article Durvalumab: A Review in Extensive-Stage SCLC, written by Zaina T. Al-Salama, was originally published electronically in SpringerLink on 03 November 2021 without open access. After publication in volume 16, issue 6, pages 857–864, AstraZeneca requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by AstraZeneca. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
The original article has been corrected.